AbbVie partners with Neomorph to develop novel degrader therapies

USA— AbbVie has entered a partnership and option-to-license agreement with Neomorph, a biotechnology company specializing in molecular glue degraders to enhance its oncology and immunology pipeline.

These innovative degraders are designed to selectively target and break down disease-causing proteins, including those previously considered “undruggable.”

The collaboration aims to introduce a groundbreaking class of treatments to address complex medical challenges.

Under the agreement, Neomorph will receive an upfront payment from AbbVie and could potentially earn up to US$1.64 billion in option fees and milestone payments.

Additionally, the company is entitled to tiered royalties on future product sales.

Founded in 2020 and headquartered in San Diego, California, Neomorph is supported by Deerfield Management Company.

It focuses on developing medicines that target proteins previously thought impossible to address.

According to Phil Chamberlain, Neomorph’s CEO, president, and co-founder, the company has spent years building a molecular glue platform with extensive proteome coverage.

Chamberlain expressed excitement about collaborating with AbbVie, a global leader in transformative oncology and immunology therapies, to tackle some of the most challenging protein targets.

In addition to the Neomorph partnership, AbbVie recently finalized its acquisition of Nimble Therapeutics, a biotechnology company specializing in oral peptide therapies.

Nimble’s lead asset, an oral peptide interleukin 23 receptor (IL23R) inhibitor, is in preclinical development and aims to treat psoriasis.

Jonathon Sedgwick, AbbVie’s global head of discovery research, highlighted the company’s enthusiasm for expanding its immunology pipeline with Nimble’s innovative oral peptide technology.

He also welcomed Nimble’s talented team, noting their shared dedication to improving care standards for individuals with autoimmune diseases.

The acquisition of Nimble was first announced in December 2024. AbbVie agreed to a US$200 million cash payment at closing, with additional interim funding opportunities outlined in the deal.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.

Newer Post

Thumbnail for AbbVie partners with Neomorph to develop novel degrader therapies

Saudi German Hospital Aseer achieves Prestigious Magnet® Recognition for Nursing Excellence

Older Post

Thumbnail for AbbVie partners with Neomorph to develop novel degrader therapies

Emcure Pharmaceuticals opens state-of-the-art R&D centre in Gujarat

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.